Background: Compared with quantitative observations, the search for qualitative changes that may characterize the immune response to Epstein–Barr virus (EBV) in multiple sclerosis (MS) has been less intense.
Objective: To examine the B-cell epitopes of antibodies against the Epstein–Barr nuclear antigen-1 (EBNA-1) and their relevance for MS, through a study in disease-discordant identical twins.
Methods: We evaluated the antibodies to all unique, maximally overlapping octapeptides of EBNA-1 in 12 pairs of monozygotic (MZ) twins (9 MS-discordant, 3 healthy), 3 non-twin patients and 2 healthy subjects. All except one of the patients were untreated. The EBV serology of these individuals had been assessed in advance using commercially available and in-house enzyme-linked immunosorbent assay (ELISA) kits, including assays for antibodies against select peptides of EBNA-1: EBNA-72 (GAGGGAGAGG) and EBNA-206 (EADYFEYHQEGGPDGE).
Results: The glycine–alanine rich domain of EBNA-1 was immunodominant in all subjects. Compared with healthy individuals, and similarly to what has been described in infectious mononucleosis (IM) patients, affected co-twins and non-twin patients had a significantly increased response to another EBNA-1 epitope (aa. 401–411).
Conclusion: In a study that controls for confounders, our data focus an EBNA-1 specificity that may be associated with MS pathogenesis.
PenderMP. Does Epstein–Barr virus infection in the brain drive the development of multiple sclerosis?Brain2009; 132: 3196–3198.
2.
AscherioABar-OrA. EBV and brain matter(s)?Neurology2010; 74: 1127–1135.
3.
SundströmPNyströmMRuuthKLundgrenE. Antibodies to specific EBNA-1 domains and HLA-DRB1*1501 interact as risk factors for multiple sclerosis. J Neuroimmunol2009; 215: 102–107.
4.
JafariNvan NieropGPVerjansGMGMOsterhausADMiddeldorpJMHintzenRQ. No evidence of intrathecal IgG synthesis to Epstein–Barr virus nuclear antigen-1 in multiple sclerosis. J Clin Virol2010; 49: 26–31.
5.
SimonKCvan der MeiIAMungerKLPonsonbyADickinsonJDwyerT. Combined effects of smoking, anti EBNA-1 antibodies, and HLA-DRB1*1501 on multiple sclerosis risk. Neurology2010; 74: 1365–1371.
6.
BaranziniSEMudjeJvan VelkinburgJCKhankhanianPKhrebtukovaIMillerNA. Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis. Nature2010; 464: 1351–1356.
7.
RistoriGCannoniSStaziMAVanacoreNCotichiniRAlfòM. Multiple sclerosis in twins from continental Italy and Sardinia: A nationwide study. Ann Neurol2006; 59: 27–34.
8.
McClainMTRappECHarleyJBJamesJA. Infectious mononucleosis patients temporarily recognize a unique, cross-reactive epitope of Epstein–Barr virus nuclear antigen-1. J Med Virol2003; 70: 253–257.
9.
JamesJAHarleyJB. Human lupus anti-spliceosome A protein autoantibodies bind contiguous surface structures and segregate into two sequential epitope binding patterns. J Immunol1996; 156: 4018–4026.
10.
McClainMTPooleBDBrunerBFKaufmanKMHarleyJBJamesJA. An altered immune response to Epstein–Barr nuclear antigen 1 in pediatric systemic lupus erythematosus. Arthritis Rheum2006; 54: 360–368.
11.
RistoriGMechelliRAndersonJMengoniFSauzulloIAnnibaliV. Antiviral immune response in patients with multiple sclerosis, healthy siblings and twins. Mult Scler2010; 12: 1527–1528.
12.
RhodesGRumpoldHKurkiPPatrickKMCarsonDAVaughanJH. Autoantibodies in infectious mononucleosis have specificity for the glycine-alanine repeating region of the Epstein–Barr virus nuclear antigen. J Exp Med1987; 165: 1026–1040.
13.
Van NoortJMVan SechelACBajramovicJJel OuagmiriMPolmanCHLassmannH. The small heat-shock protein alpha B-crystallin as candidate autoantigen in multiple sclerosis. Nature1995; 375: 798–801.
14.
Van SechelACBajramovicJJvan StopdonkMJPersoon-DeenCGeutskensSBvan NoortJM. EBV-induced expression and HLA-DR restricted presentation by human B cells of alpha B-crystallin, a candidate autoantigen in multiple sclerosis. J Immunol1999; 162: 129–135.
15.
RandKHHouckHDenslowNDHeilmanKM. Molecular approach to find target(s) for oligoclonal bands in multiple sclerosis. J Neurol Neurosurg Psychiatry1998; 65: 48–55.
16.
HislopADTaylorGSSauceDRickinsonAB. Cellular responses to viral infections in humans: lessons from Epstein–Barr virus. Annu Rev Immunol2007; 25: 587–617.
17.
LünemannJDHuppkePRobertsSBrückWGärtnerJMünzC. Broadened and elevated humoral immune response to EBNA-1 in pediatric multiple sclerosis. Neurology2008; 71: 1033–1035.
18.
MunchMHvasJChristensenTMøller-LarsenAHaarS. A single subtype of Epstein–Barr virus in members of multiple sclerosis clusters. Acta Neurol Scand1998; 98: 195–199.
BrennanRMBurrowsJMBellMJBromhamLCsurhesPALenarczykA. Strains of Epstein–Barr virus infecting multiple sclerosis patients. Mult Scler2010; 6: 643–651.
21.
SimonKCYangYMungerKLAscherioA. EBNA1 and LMP1 variants in multiple sclerosis cases and controls. Acta Neurol Scand2010; [Epub ahead of print].
22.
SelinLKBrehmMANaumovYNCornbergMKimSKCluteSC. Memory of mice and men: CD8+ T-cell cross-reactivity and heterologous immunity. Immunol Rev2006; 211: 164–181.
23.
LünemannJDJelcicIRobertsSLutterottiATackenbergBMartinR. EBNA-1 specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2. J Exp Med2008; 205: 1763–1773.
24.
RecherMLangKSNavariniAHunzikerLLangPAFinkK. Extralymphatic virus sanctuaries as a consequence of potent T cell activation. Nat Med2007; 13: 1316–1323.
